However, in advanced NSCLC, only a few drugs, such as docetaxel and pemetrexed, are used as second-line treatment options, along with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) like erlotinib and gefitinib [3,4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.